Mass. Movers

Vertex up on hepatitis deals

Vertex’s new headquarters, under construction in South Boston.

David L. Ryan/Globe Staff

Vertex’s new headquarters, under construction in South Boston.


Vertex Pharmaceuticals Inc. said it has entered into deals with GlaxoSmithKline and Janssen Pharmaceuticals to work on potential treatments for hepatitis C. Cambridge-based Vertex already has a hepatitis C drug on the market called Incivek. The separate studies with the British drug company and Janssen, unit of Johnson & Johnson, call for VX-135, another Vertex hepatitis C drug candidate, to be tested in combinations with pills made by those firms. Those studies are scheduled to start early next year.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of